Fuhong Hanxuan "Adamu single resistance" was approved for listing

Adamo Monoantitor (Shumeile) is the first fully humanized anti-tumor necrotic cause of death- α (TNF-α) monoclonal antibody developed by Abbvie, which was first approved for import in China on February 26, 2010, and its antibody sequence patent expires in China in 2017.
In China, Shumei is pleased to be listed in 2010 and is currently approved for 3 adaptations of moderate to severe rheumatoid arthritis in adults, moderate to severe scoliosis in adults with poor routine treatment, and severe chronic plaque-like psoriasis in adults.
addition, Shumeile was included in the CDE's March 2019 List of The Second Batch of Clinically Urgently Needed Foreign Drugs for the Treatment of Staphylococcitis.
During the 2019 health care negotiations, Shumeile reduced its price by 59% and successfully entered health insurance, after it was actively reduced from 7641.52 to 3,160 yuan, a cumulative decline of more than 83%, which will put great competitive pressure on subsequent approval of domestic biosypole drugs.
November 7, 2019, the first domestic Adamo monobial-like drug was approved for sale from Biotai (commodity name: Greeley), and on December 6, the same year, Haizheng Pharmaceuticals' Adamo single-to-biosychic drug was approved (commodity name: Anjianin).
The Insight database shows that the three currently listed Adamo monobial-like drugs are priced consistently, all at $1,150/branch/0.8ml:40mg.
2020, the half-yearly report shows that Greeley's domestic sales in the third quarter were 57.7 million yuan, with cumulative sales of 100 million yuan in the first three quarters.
With the success of the original research into health insurance, the penetration rate of the domestic market is expected to further increase, according to Frost Sullivan reported that China's Adamo mono-biosygenic drug market is expected to increase to 4.7 billion yuan in 2023, and will reach 11.5 billion yuan in 2030, if the marketing is done well may be able to share a piece.
At present, the domestic Adamo single anti-biosynthic drug research and development is very hot, in addition to Baiotai, Haizheng, Fuhong Hanyu and Xinda, Junshi biological, Zhengda Tianqing biosychic drugs are also on the market review and approval.
Adamu single anti-biosynthic drugs in the research enterprises () from the figure above can be seen, Adamo single anti-biosynthic drugs in the domestic research enterprises more than 20, the variety in the domestic competition has been white heat.
And on the relevant developments of the National Health Insurance Administration, it is currently studying the relevant policies for centralized procurement of biological products, biosynthic drugs are not a restricted area for centralized procurement, on the basis of taking into account the similarity of biosynthic drugs, the stability of enterprise capacity and supply chain, clinical alternatives to specific products and other factors, will be carried out in due course.
Thus, the collection of biosynthic drugs is also imminent, according to Insight database statistics, currently in line with the collection of biosynthic drugs in Adamo single resistance bear the brunt, followed by beva bead monoanti and lycoxi monoantigen resistance, but the industry also had expectations of this, but when the collection really arrived estimated to be a blood rain.
。